2929 related articles for article (PubMed ID: 20129555)
1. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
[TBL] [Abstract][Full Text] [Related]
2. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies.
Steinberg DH; Mintz GS; Mandinov L; Yu A; Ellis SG; Grube E; Dawkins KD; Ormiston J; Turco MA; Stone GW; Weissman NJ
JACC Cardiovasc Interv; 2010 May; 3(5):486-94. PubMed ID: 20488404
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
4. Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials.
Doi H; Maehara A; Mintz GS; Weissman NJ; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Stone GW
Circ Cardiovasc Interv; 2008 Oct; 1(2):111-8. PubMed ID: 20031665
[TBL] [Abstract][Full Text] [Related]
5. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
Stone GW; Ellis SG; Colombo A; Grube E; Popma JJ; Uchida T; Bleuit JS; Dawkins KD; Russell ME
JACC Cardiovasc Interv; 2011 May; 4(5):530-42. PubMed ID: 21596326
[TBL] [Abstract][Full Text] [Related]
7. Angiographic and intravascular ultrasound follow up of paclitaxel- and sirolimus-eluting stent after poststent high-pressure balloon dilation: from the poststent optimal stent expansion trial.
Park SM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y; Kang WC; Ahn T; Kim BK; Oh SJ; Jeon DW; Yang JY
Catheter Cardiovasc Interv; 2011 Jan; 77(1):15-21. PubMed ID: 20928842
[TBL] [Abstract][Full Text] [Related]
8. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
[TBL] [Abstract][Full Text] [Related]
9. Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials.
Aoki J; Mintz GS; Weissman NJ; Mann JT; Cannon L; Greenberg J; Grube E; Masud AR; Koglin J; Mandinov L; Stone GW
JACC Cardiovasc Interv; 2008 Apr; 1(2):161-7. PubMed ID: 19463294
[TBL] [Abstract][Full Text] [Related]
10. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
11. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program.
Turco MA; Ormiston JA; Popma JJ; Hall JJ; Mann T; Cannon LA; Webster MW; Mishkel GJ; O'Shaughnessy CD; McGarry TF; Mandinov L; Dawkins KD; Baim DS
JACC Cardiovasc Interv; 2008 Dec; 1(6):699-709. PubMed ID: 19463387
[TBL] [Abstract][Full Text] [Related]
12. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
13. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
[TBL] [Abstract][Full Text] [Related]
14. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
[TBL] [Abstract][Full Text] [Related]
15. Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR trial.
Koizumi T; Fitzgerald PJ; Honda Y; Ellis SG; Kent K; Martin SL; Brown CL; Masud AR; Patterson JB; Greenberg J; Friedman M; Uchida T; Stone GW
Cardiovasc Revasc Med; 2010; 11(3):140-8. PubMed ID: 20599163
[TBL] [Abstract][Full Text] [Related]
16. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
[TBL] [Abstract][Full Text] [Related]
17. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
[TBL] [Abstract][Full Text] [Related]
18. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
[TBL] [Abstract][Full Text] [Related]
19. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents.
Hsieh IC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Lin FC; Chen CC
Coron Artery Dis; 2013 May; 24(3):224-30. PubMed ID: 23571311
[TBL] [Abstract][Full Text] [Related]
20. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
